Levi & Korsinsky is investigating the Board of Directors of Zalicus, Inc. (“Zalicus” or “the Company”) (NasdaqCM:ZLCS) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Epirus Biopharmaceuticals.

Click here to learn more about the action http://zlk.9nl.com/zalicus-zlcs, or call: 877-363-5972. There is no cost or obligation to you.

Under the terms of the transaction, Zalicus shareholders will own a percentage of the post-merger company; this percentage is subject to an adjustment at closing based on the level of Zalicus net cash. Based on Zalicus’ net cash as of April 16, 2014, the day the merger was announced, Zalicus shareholders would own just 14% of the combined company. The investigation concerns whether the Zalicus Board of directors breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Epirus Biopharmaceuticals is underpaying for Zalicus shares.

If you own Zalicus common stock and wish to obtain additional information, please contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/zalicus-zlcs.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s 26 attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

Copyright Business Wire 2010